271 related articles for article (PubMed ID: 25411597)
1. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
Kashiwagi A; Kazuta K; Yoshida S; Nagase I
J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
Ishihara H; Yamaguchi S; Nakao I; Asahina S; Sakatani T
Diabetol Int; 2019 Jan; 10(1):37-50. PubMed ID: 30800562
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kaku K; Isaka H; Toyoshima J; Sakatani T
Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Kaku K; Isaka H; Sakatani T; Toyoshima J
Diabetes Obes Metab; 2019 Oct; 21(10):2284-2293. PubMed ID: 31173455
[TBL] [Abstract][Full Text] [Related]
6. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Kaku K; Isaka H; Sakatani T; Toyoshima J
J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
[TBL] [Abstract][Full Text] [Related]
7. Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial.
Min KW; Ku BJ; Lee JH; Kim MS; Ahn KJ; Lee MK; Kokubo S; Yoshida S; Cho HJ; Cha BS
Diabetes Metab J; 2017 Apr; 41(2):135-145. PubMed ID: 28447440
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
Ishihara H; Yamaguchi S; Nakao I; Sakatani T
Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
[TBL] [Abstract][Full Text] [Related]
11. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Kashiwagi A; Yoshida S; Kawamuki K; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Akiyama N; Kondo Y; Ogihara T
Diabetol Int; 2017 Mar; 8(1):76-86. PubMed ID: 30603310
[TBL] [Abstract][Full Text] [Related]
12. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
[TBL] [Abstract][Full Text] [Related]
13. Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Diabetes Ther; 2020 Apr; 11(4):951-964. PubMed ID: 32166619
[TBL] [Abstract][Full Text] [Related]
14. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
[TBL] [Abstract][Full Text] [Related]
18. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
Ohkura T
World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
[TBL] [Abstract][Full Text] [Related]
20. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
